Trial Profile

A Phase Ib/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Jun 2026 According to a Nouscom media release, data published from the successfully completed phase 1b trial were published in Science Translational Medicine.
01 Jun 2026 According to a Nouscom media release, the FDA granted Fast Track Designation to NOUS-209 for the prevention of Lynch Syndrome-associated cancers in carriers of genetically confirmed mismatch repair (MMR) mutations and this designation is supported by Phase 1b/2 clinical data in Lynch Syndrome carriers.
16 Jan 2026 According to Nouscom media release, data from the trial were presented in Nature Medicine

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com